Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee ...

Preclinical data highlight that PKM2 modulation inhibits several important mechanisms underlying atopic dermatitis pathologySYX-5219 is a ...

Topical corticosteroids are recommended as first-line treatment for all levels of atopic dermatitis, as well as for ...

Nektar Therapeutics (NASDAQ:NKTR) shares climbed 3.6% on Monday after the biotech firm unveiled encouraging new data showing ...

SIM0278 benefits from Simcere’s protein engineering platform, embodying mutations to decrease binding to effector T cells.

Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...

The Phase 2b ADAPTIVE trial is a randomized, placebo-controlled dose-finding study designed to evaluate the efficacy and safety of various dose regimens of IMG-007 in adults with moderate-to-severe AD ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...

Please provide your email address to receive an email when new articles are posted on . Results showed high-dose upadacitinib was the most effective treatment, yet it increased any adverse event.

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

How do dermatologists diagnose atopic dermatitis? To diagnose atopic dermatitis, also called eczema, a board-certified dermatologist carefully examines your (or your child's) skin and asks questions. ...

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, today announced it has been ...